drugset / Trial / NCT06971211
Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
NaSingle-groupOpen-labelTreatment
Summary
This study is an open label, single arm, multicenter clinical trial. The aim of this study is to evaluate the efficacy, safety, and quality of life of radiotherapy combined with Fuzuloparib and Abiraterone Acetate Tablets（Ⅱ） as first-line treatment for castration resistant prostate cancer patients. The study aims to enroll 40 eligible subjects with PSA response rate (PSA 50) as the primary endpoint.
Timeline
- Start
- 2024-11-27
- Primary completion
- 2027-10-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 300 mg | Oral |
| Subject | Fluzoparib | Small molecule | 150 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |